PTEN Research’s Post

Calling out for applications – submission deadline approaching! PTEN Research is inviting applications to advance the understanding of disease mechanisms that drive PHTS manifestations. Funding is available for basic and translational research projects addressing key knowledge gaps in the pathobiology of PHTS. We encourage projects that utilise PHTS patient-derived induced pluripotent stem cells that will be available through a biorepository later in 2024. Funding requests of up to 220,000 GBP (or the equivalent in the host institution’s local currency) will be considered, for a project of 2 to 3-years in length. Application deadline is 28 June 2024. Full details and how to apply can be found at https://lnkd.in/eiVUwV28 About PTEN Research PTEN Research is a UK-registered charity. We fund and facilitate research that will lead to new and better treatment for PHTS, a rare condition which currently has no health authority approved therapies. We do this by funding research projects and bringing together a global network of PHTS focussed experts and other key partners. About PHTS In PHTS, germline mutation of the PTEN gene increases PI3K/AKT/mTOR signalling, a key pathway regulating cell growth. Individuals with PHTS have an increased predisposition to cancer as well as various significant co-morbidities, including developmental delay, autism spectrum disorder, polyposis, vascular anomalies and hamartomas. The prevalence of PHTS is estimated to be 1:200,000 but the condition is likely under-diagnosed. #PTENResearch #PHTS #PTEN

Final call for applications – submission deadline in 2 weeks! PTEN Research is inviting applications to advance the understanding of disease mechanisms that drive PHTS manifestations. Funding is available for basic and translational research projects addressing key knowledge gaps in the pathobiology of PHTS. We encourage projects that utilise PHTS patient-derived induced pluripotent stem cells that will be available through a biorepository later in 2024. Funding requests of up to 220,000 GBP (or the equivalent in the host institution’s local currency) will be considered, for a project of 2 to 3-years in length. Application deadline is 28 June 2024. Full details and how to apply can be found on https://lnkd.in/eiVUwV28 About PTEN Research PTEN Research is a UK-registered charity. We fund and facilitate research that will lead to new and better treatment for PHTS, a rare condition which currently has no health authority approved therapies. We do this by funding research projects and bringing together a global network of PHTS focussed experts and other key partners. About PHTS In PHTS, germline mutation of the PTEN gene increases PI3K/AKT/mTOR signalling, a key pathway regulating cell growth. Individuals with PHTS have an increased predisposition to cancer as well as various significant co-morbidities, including developmental delay, autism spectrum disorder, polyposis, vascular anomalies and hamartomas. The prevalence of PHTS is estimated to be 1:200,000 but the condition is likely under-diagnosed. #PTENResearch #PHTS #PTEN

Call for Applications: Improving understanding of disease mechanisms of PTEN hamartoma tumour syndrome (PHTS)   PTEN Research is a UK-registered charity. We fund and facilitate research that will lead to new and better treatment for PHTS, a rare condition which currently has no health authority approved therapies. We do this by funding research projects and bringing together a global network of PHTS focussed experts and other key partners.   We are now inviting research applications to advance the understanding of disease mechanisms that drive PHTS manifestations.   Funding is available for basic and translational research projects addressing key knowledge gaps in the pathobiology of PHTS. We encourage projects that utilise PHTS patient-derived induced pluripotent stem cells that will be available through a biorepository later in 2024.   Funding requests of up to 220,000 GBP (or the equivalent in the host institution’s local currency) will be considered, for a project of 2 to 3-years in length. Application deadline is 28 June 2024.   Please see our https://lnkd.in/eiVUwV28 for more information and how to apply.   About PHTS   In PHTS, germline mutation of the PTEN gene increases PI3K/AKT/mTOR signalling, a key pathway regulating cell growth. Individuals with PHTS have an increased predisposition to cancer as well as various significant co-morbidities, including developmental delay, autism spectrum disorder, polyposis, vascular anomalies and hamartomas. The prevalence of PHTS is estimated to be 1:200,000 but the condition is likely under-diagnosed. 

We are immensely thankful for the support of Oxford Nanopore Technologies in this pioneering childhood cancer project, which seeks to improve outcomes for childhood cancer in Ghana. "This initiative focuses on the PROGRESS Study, which aims to improve survival rates for childhood cancers in low- and middle-income countries where survival rates can be lower than 30%, compared to over 80% in high-income countries. This project, funded in part by LifeArc, has the potential to play a pivotal role in contributing towards the World Health Organization's goal of a 60% survival rate by 2030 for all children with cancer globally." Read more: https://lnkd.in/dFkuQmDE #ChildhoodCancerAwarenessMonth #GoldSeptember #CancerResearch #ChildhoodCancer #AcuteLymphoblasticLeukemia #PaediatricCancer Korle Bu Teaching Hospital Greater Accra Regional Hospital, Ridge Komfo Anokye Teaching Hospital Newcastle University

For Africa, in Africa - with the potential to advance the global standard of care 👏 🌍 --> 🗺 How's that for progress? #capacitybuilding #africa #leukaemia #dna #sequencing #nanopore

PTEN Research is excited to share the latest addition to its website – 'PHTS Research Tools' that collates sources of information on clinical and pre-clinical resources relevant to PHTS. https://lnkd.in/e6UM75X6   In line with our mission to fund and facilitate research that will lead to better treatments and improved outcomes for PHTS, we hope this online resource, that includes information on patient cohorts, existing clinical trials data, and laboratory and animal models, will stimulate new ideas and drive further collaboration within the PHTS community, not only to improve the understanding of PHTS but also to accelerate future research.   Resources generated from our own funding as well those from other groups and funders are included to create as comprehensive a resource as possible. New tools, models and datasets will be added as they become available.   If you have any queries or would like us to consider adding a resource you have generated, please get in touch research@ptenresearch.org. Our Innovation Award programme is currently accepting new applications, for more information https://lnkd.in/eDa7PE5d About PTEN Research PTEN Research is a UK-registered charity. We fund and facilitate research that will lead to new and better treatment for PHTS, a rare condition which currently has no health authority approved therapies. We do this by funding research projects and bringing together a global network of PHTS focussed experts and other key partners. About PHTS   In PHTS, germline mutation of the PTEN gene increases PI3K/AKT/mTOR signalling, a key pathway regulating cell growth. Individuals with PHTS have an increased predisposition to cancer as well as various significant co-morbidities, including developmental delay, autism spectrum disorder, polyposis, vascular anomalies and hamartomas. The prevalence of PHTS is estimated to be 1:200,000 but the condition is likely under-diagnosed. #PTENResearch #PHTS #PTEN

To help launch and support your PTEN research 🚀🔬

📢 Call for Papers: Special Issue on Advances in Oral Cancer Treatment Oral cancer remains a significant global health issue, characterized by high morbidity and mortality rates. Our new special issue, Advances in Oral Cancer Treatment, is now live and invites researchers and clinicians to contribute cutting-edge research and innovative approaches to understanding, diagnosing, and treating oral cancer. 🔬 Focus Areas Include (but are not limited to): 💡 Molecular and genetic insights into oral cancer 💡 Novel diagnostic techniques 💡 Development of targeted therapies and immunotherapies 🖊️ Submit Your Research: We welcome original research articles and review articles that can contribute to this important field. This special issue is poised to become a valuable resource for oncologists and researchers dedicated to improving outcomes for oral cancer patients. 👥 Guest Editors: Prof. Shun-Fa Yang, Chung Shan Medical University, Taichung, Taiwan. Prof. Shih-Chi Su, Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung, Taiwan. Join us in advancing the field of oral cancer together. We look forward to your valuable contributions. 🔗 Learn More and Submit: https://lnkd.in/d7F8qUdy #OralCancer #CancerResearch #Oncology #MedicalResearch #CallForPapers #SpecialIssue #CancerTreatment #OralCancerTreatment #MolecularBiology #Genetics #Immunotherapy #TargetedTherapies #ResearchCollaboration #OncologyResearch #TechSciencePress

🚀 Discovering #i4KIDS researchers network!  i4KIDS is made up of more than 90 research groups belonging to our members focused on fetal, paediatrics and maternal health. 🧑🔬 Today, we are proud to present the work of Dr. Laura Belver and her team in paediatric oncology, focusing on Juvenile Myelomonocytic Leukemia (JMML) at Josep Carreras Leukaemia Research Institute.  💡 Research Focus: Since 2020, this research group is been dedicated to uncovering JMML's molecular mechanisms and exploring new therapeutic strategies. Using epigenetics, systems biology, genomics, and biochemistry, we aim to identify precise diagnostic criteria and therapeutic targets. 🎯 Goals: Its objectives include establishing a national JMML sample repository, refining diagnostic criteria, and developing tailored therapies to improve patient outcomes. 🌟 Impact and Collaboration: This research aims to enhance JMML diagnosis and treatment, working closely with clinical teams to ensure rapid translation of discoveries into clinical practice. 🔍 Addressing Key Questions: They are tackling critical questions about non-coding somatic mutations, prognosis prediction, and therapeutic targets for JMML-specific treatments. More information ⏬  https://lnkd.in/ecD-rQkM #i4KIDS #i4KIDSEUROPE #JMMLResearch #PaediatricOncology #ResearchInnovation #PaediatricsInnovation #Paediatrics